Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Delirium 2Sarcoma, Alveolar Soft Part 1Recurrence 1Neurotoxicity Syndromes 1Neoplasm Metastasis 1Hematologic Neoplasms 1

Interventions

neurotropin 1haloperidol decanoate 1fludarabine phosphate 1fludarabine 1axicabtagene ciloleucel 1Temozolomide 1Tadalafil 1Surveys and Questionnaires 1Simvastatin 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Nutritional Status 1N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid 1Lorazepam 1Interleukin 1 Receptor Antagonist Protein 1Exercise Therapy 1Exercise 1Dexamethasone 1Cyclophosphamide 1Bendamustine Hydrochloride 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurotoxicity Syndromes × Lorazepam × 1 year × Clear all
NCT01949662 2026-02-13

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
93 enrolled 14 charts
Other hematologic neoplasm

Delirium, Hematologic Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡